Harprit Bajwa, DPM
Primary Podiatric Medicine · Cameron Park, CANPI 1073563938
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,684 of the $2,748 with a category attached, or 61.3%. 16 manufacturers reported payments, led by Evolution Surgical, Inc at 53.5% of the total. Reporting peaked in 2024 at $2,155 and has fallen 88.5% since, to $247 in 2025.
Across 43 payments — averaging $63.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Evolution Surgical, Inc$1K
- Arthrex$640
- Biotissue Holdings Inc.$93
- Johnson & Johnson$92
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$91
- Bioventus LLC$79
- plus $281 from 10 others
What the payments were for
- Travel & lodging$1,68461%
- Food & beverage$1,06439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Evolution Surgical, Inc | 7 | $1,471 |
| Arthrex | 7 | $640 |
| Biotissue Holdings Inc. | 6 | $93 |
| Johnson & Johnson(2 entities) | 4 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $91 |
| Bioventus LLC | 1 | $79 |
| Stryker | 1 | $74 |
| Merck | 4 | $50 |
| Organogenesis Inc. | 1 | $34 |
| Treace Medical Concepts, Inc. | 1 | $23 |
| Paragon 28, Inc. | 1 | $23 |
| Smith+Nephew | 1 | $19 |
| AbbVie | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $6 |
How this compares
$2,748 in reported general payments places this provider in the 75th percentile of 59 primary podiatric medicine providers in California.
See all primary podiatric medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 91 | $1,379 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 26 | $544 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 34 | $302 |
| Diclofenac Sodium | 15 | $296 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $296 |
| Terbinafine Hcl | 19 | $263 |
| Doxycycline Hyclate | 23 | $179 |
| Ondansetron OdtOndansetron | 16 | $156 |
| Meloxicam | 46 | $149 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $110 |
| Amitriptyline Hcl | 14 | $96 |
| Cephalexin | 23 | $82 |
Paid to pharmacies, not to this prescriber.
Other primary podiatric medicine in Cameron Park
- James WangLos Angeles$250K
- Adam ShapiroUpland$21K
- Ali GhorbanifarajzadehBakersfield$17K
- Abid ChaudhryArleta$11K
- Matthew GarrisonSacramento$7K
- Linh HuynhTurlock$7K
- Yvette CanabaSantee$5K
- David KhakshoorLos Angeles$4K
- Katrina SergeevaVista$4K
- Christyn MarshallDanville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.